Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors

Go Back to All Clinical Trials

Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Advanced Solid Tumors
Age: Between 18 Year(s) - 99 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. NSCLC, previously treated with immunotherapy, chemotherapy, and KRASG12C (OFF) inhibitors
2. NSCLC, previously treated with immunotherapy and chemotherapy, naïve to KRASG12C (OFF) inhibitors
3. Solid tumors, previously treated, naïve to KRASG12C (OFF) inhibitors

You may not be eligible for this study if the following are true:

1. Primary CNS tumor(s)
2. Untreated brain or leptomeningeal metastases
3. History of interstitial lung disease (ILD) requiring treatment with glucocorticoids, history of noninfectious pneumonitis requiring glucocorticoids, or any active ILD or pneumonitis

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies